Valuation: Exagen Inc.

Market Cap 181M 162M 150M 136M 254M 17.22B 258M 1.8B 713M 9.01B 679M 665M 28.51B P/E 2026 *
-11.3x
P/E 2027 * -14.5x
Enterprise Value 181M 162M 150M 136M 254M 17.22B 258M 1.8B 713M 9.01B 679M 665M 28.51B EV / Sales 2026 *
2.45x
EV / Sales 2027 * 2.22x
Free-Float
61.54%
Yield 2026 *
-
Yield 2027 * -
1 day+2.75%
1 week+0.54%
Current month-8.12%
1 month-14.33%
3 months+59.62%
6 months+176.67%
Current year+22.86%
1 week 7.05
Extreme 7.05
8.11
1 month 7.05
Extreme 7.05
9.22
Current year 2.59
Extreme 2.59
9.22
1 year 2.59
Extreme 2.59
11.98
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
14.85
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 17/10/2022
Director of Finance/CFO 57 01/09/2024
Chief Tech/Sci/R&D Officer - 23/06/2025
Director TitleAgeSince
Chairman 73 19/01/2023
Director/Board Member 63 30/07/2019
Director/Board Member 56 17/06/2021
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Sell

Chief Financial Officer

-22,185 0.0916%
12/03/26 Free

Chief Financial Officer

126,511 0.5582%
12/03/26 Free

Chief Executive Officer

250,000 1.1031%
Change 5-day change 1-year change 3-year change Capi.($)
+2.75%+0.54%-37.54%+378.85% 181M
-1.01%-0.16%+12.94%+36.11% 118B
-0.80%+2.28%+4.08%+109.76% 101B
+0.24%+1.37%+110.33%+936.88% 58.36B
-0.26%+3.45%-5.19%+88.31% 29.26B
+0.29%+3.47%+18.04%+60.21% 26.75B
+0.44%+3.42%+33.36%+85.09% 26.73B
+0.19%+0.96%+27.84%+403.56% 21.66B
-0.71%+1.79%-17.15%-7.26% 20.89B
-19.92%-19.22%-17.13%+52.99% 14.01B
Average -1.88%-0.19%+12.96%+214.45% 41.69B
Weighted average by Cap. -1.11%+0.88%+23.03%+205.98%

Financials

2026 *2027 *
Net sales 73.91M 66.09M 61.15M 55.37M 104M 7.03B 105M 736M 291M 3.68B 277M 271M 11.65B 81.51M 72.89M 67.44M 61.06M 114M 7.76B 116M 811M 321M 4.06B 306M 299M 12.84B
Net income -15.93M -14.25M -13.18M -11.93M -22.34M -1.52B -22.7M -159M -62.74M -793M -59.8M -58.52M -2.51B -13.38M -11.96M -11.07M -10.02M -18.76M -1.27B -19.07M -133M -52.69M -666M -50.22M -49.14M -2.11B
Net Debt - -
Projected Income Statement - Annual - Exagen Inc.
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
26/10/26 $7.470 +2.75% 191,379
23/10/26 $7.270 -2.81% 222,793
22/10/26 $7.480 -5.08% 219,157
21/10/26 $7.880 +6.34% 285,817
20/10/26 $7.410 -0.27% 425,293
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Exagen Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.470USD
Average target price
10.57USD
Spread / Average Target
+41.52%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Exagen Inc.